Dual PDE3/4 and PDE4 Inhibitors: Novel Treatments For COPD and Other Inflammatory Airway Diseases

Novel Class of Benzoic Acid Ester Derivatives as Potent PDE4 Inhibitors for Inhaled Administration in the Treatment of Respiratory Diseases

(2014) Elisabetta Armani et al.   JOURNAL OF MEDICINAL CHEMISTRY

Transcriptome sequencing (RNA-Seq) of human endobronchial biopsies: asthmaversuscontrols

(2013) Ching Yong Yick et al.   EUROPEAN RESPIRATORY JOURNAL

The Selective Phosphodiesterase 4 Inhibitor Roflumilast and Phosphodiesterase 3/4 Inhibitor Pumafentrine Reduce Clinical Score and TNF Expression in Experimental Colitis in Mice

(2013) Florian Rieder et al.   PLoS One

Roflumilast Inhibits Respiratory Syncytial Virus Infection in Human Differentiated Bronchial Epithelial Cells

(2013) Manuel Mata et al.   PLoS One

Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis

(2013) Barbara Yawn et al.   International Journal of Chronic Obstructive Pulmonary Disease

Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials

(2013) Lui G Franciosi et al.   Lancet Respiratory Medicine

Phosphodiesterase inhibitors. Part 5: Hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration

(2012) Koji Ochiai et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages

(2011) J. Milara et al.   CLINICAL AND EXPERIMENTAL ALLERGY

In Vivo Characterization of GSK256066, a High-Affinity Inhaled Phosphodiesterase 4 Inhibitor

(2011) A. T. Nials et al.   JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS

Critical Modifier Role of Membrane-Cystic Fibrosis Transmembrane Conductance Regulator-Dependent Ceramide Signaling in Lung Injury and Emphysema

(2010) M. Bodas et al.   JOURNAL OF IMMUNOLOGY

PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF-κB-independent manner

(2010) Lirlândia P. Sousa et al.   JOURNAL OF LEUKOCYTE BIOLOGY

Roflumilast for the treatment of chronic obstructive pulmonary disease

(2010) Klaus F Rabe   Expert Review of Respiratory Medicine

A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD

(2009) J. Vestbo et al.   EUROPEAN RESPIRATORY JOURNAL

Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials

(2009) Peter MA Calverley et al.   LANCET

Effect of Pharmacotherapy on Rate of Decline of Lung Function in Chronic Obstructive Pulmonary Disease

(2008) Bartolomé R. Celli et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca2+responses in endothelial cells

(2008) M Campos-Toimil et al.   BRITISH JOURNAL OF PHARMACOLOGY

Nicotine and oxidative cigarette smoke constituents induce immune-modulatory and pro-inflammatory dendritic cell responses

(2008) Robert Vassallo et al.   MOLECULAR IMMUNOLOGY

Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 strain

(2007) Hiroaki Mori et al.   AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY

A Major Functional Role for Phosphodiesterase 4D5 in Human Airway Smooth Muscle Cells

(2007) Charlotte K. Billington et al.   AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY

Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition

(2007) E. Dony et al.   EUROPEAN RESPIRATORY JOURNAL